Pipeline
Product Discovery and Development
pipeline
Projects identified, prioritized, and progressing through drug discovery and development
Shown below are five first-in-class programs entered into our pipeline. Additional targets are already identified for future pipeline entry or partnering. Potentially responsive patient subgroups within each indication are being defined for each project. All programs have at least tool compounds available now, and some have leads identified.
IMIDomics pipeline focuses on new targets by design
Additional indications have been identified
Case study
IMB1001 modulates CD226 signaling in both innate and adaptive immunity
Polygenic associations with expression of target pathways genes points to a marker that identifies potentially responsive patients
Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases
Five classes of SLE defined by IMIDOMICS
Class-specific clinical features identified
Demonstrated drug targets
ROBUST CLASS PREDICTORS ARE REPLICATED
BIOMARKER TO ENRICH FOR DRUG RESPONSE
